The Danish drugmaker Novo Nordisk contends that semaglutide, the active ingredient in Ozempic and Wegovy, is too complex for ...
The GLP-1 phenomenon is making the fragmentation and dysfunction of the U.S. health care system even more apparent.
Novo Nordisk wants the Food and Drug Administration (FDA) to prevent compounding pharmacies from manufacturing their own ...